endometrial cancer

ArriVent BioPharma wins FDA clearance for ARR-002, a first-in-class dual-target ADC targeting ovarian and endometrial cancers, with Phase 1 trials expected in H2 2026.

Acrivon highlights preclinical data for ACR-368 and ACR-2316 combination therapies at AACR 2026, showing synergies with checkpoint inhibitors and ADCs.

Acrivon Therapeutics presents preclinical data at AACR 2026 demonstrating strong synergy between its CHK1/2 and WEE1 inhibitors with ADC payloads and immunotherapies.

ArriVent BioPharma presents preclinical data on firmonertinib and ARR-002 ADC at 2026 AACR Annual Meeting, highlighting oncology pipeline progress.